In vitro activity of the novel beta-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China-论文-万方医学网

In vitro activity of the novel beta-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China

导出原文传递

翻译打印收藏纠错

作者： Wang, Xiaojuan ^[1] ; Zhao, Chunjiang ^[2] ; Wang, Qi ; Wang, Zhanwei ; Liang, Xinyue ; Zhang, Feifei ; Zhang, Yawei ; Meng, Han ; Chen, Hongbin ; Li, Shuguang ; Zhou, Chengcheng ; Li, Henan ; Wang, Hui

作者单位： Dept Clin Lab,Peking Univ Peoples Hosp ^[1] Everest Med US Ltd ^[2]

关键词 URINARY-TRACT-INFECTIONS EMERGENCE UPDATE

发布时间 2022-06-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

In vitro activity of the novel beta-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China

相似文献

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

In vitro activity of the novel beta-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China

相似文献

相关期刊

检索历史清除